Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

Ann Oncol. 2017 Apr 1;28(4):898-899. doi: 10.1093/annonc/mdw667.
No abstract available

Publication types

  • Letter
  • Meta-Analysis

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Renal Cell / blood supply
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / surgery*
  • Chemotherapy, Adjuvant
  • Humans
  • Indoles / therapeutic use*
  • Kidney Neoplasms / blood supply
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / surgery*
  • Molecular Targeted Therapy
  • Pyrroles / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Sunitinib

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Sunitinib